These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 28034361)

  • 1. Formulation and Optimization of Candesartan Cilexetil Nano Lipid Carrier: In Vitro and In Vivo Evaluation.
    Paudel A; Ameeduzzafar ; Imam SS; Fazil M; Khan S; Hafeez A; Ahmad FJ; Ali A
    Curr Drug Deliv; 2017; 14(7):1005-1015. PubMed ID: 28034361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharmacokinetic and pharmacodynamic evaluation.
    Dudhipala N; Veerabrahma K
    Drug Deliv; 2016; 23(2):395-404. PubMed ID: 24865287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of surface stabilized candesartan cilexetil nanocrystals with enhanced dissolution rate, permeation rate across CaCo-2, and oral bioavailability.
    Jain S; Reddy VA; Arora S; Patel K
    Drug Deliv Transl Res; 2016 Oct; 6(5):498-510. PubMed ID: 27129488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Solid lipid nanoparticles loading candesartan cilexetil enhance oral bioavailability: in vitro characteristics and absorption mechanism in rats.
    Zhang Z; Gao F; Bu H; Xiao J; Li Y
    Nanomedicine; 2012 Jul; 8(5):740-7. PubMed ID: 21930110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and in vitro/in vivo performance of self-nanoemulsifying drug delivery systems loaded with candesartan cilexetil.
    AboulFotouh K; Allam AA; El-Badry M; El-Sayed AM
    Eur J Pharm Sci; 2017 Nov; 109():503-513. PubMed ID: 28889028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Candesartan Cilexetil Formulations in Mesoporous Silica: Preparation, Enhanced Dissolution In Vitro, and Oral Bioavailability In Vivo.
    Guan H; Wang M; Yu S; Wang C; Chen Q; Chen Y; Zhang W; Fan J
    J Pharm Sci; 2024 Oct; 113(10):3045-3053. PubMed ID: 39094942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative study of nisoldipine-loaded nanostructured lipid carriers and solid lipid nanoparticles for oral delivery: preparation, characterization, permeation and pharmacokinetic evaluation.
    Dudhipala N; Janga KY; Gorre T
    Artif Cells Nanomed Biotechnol; 2018; 46(sup2):616-625. PubMed ID: 29688077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and characterization of solid oral dosage form incorporating candesartan nanoparticles.
    Nekkanti V; Pillai R; Venkateshwarlu V; Harisudhan T
    Pharm Dev Technol; 2009; 14(3):290-8. PubMed ID: 19235553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New supersaturating drug delivery system as strategy to improve apparent solubility of candesartan cilexetil in biorelevant medium.
    Pinto JMO; Leão AF; Alves GF; Mendes C; França MT; Fernandes D; Stulzer HK
    Pharm Dev Technol; 2020 Jan; 25(1):89-99. PubMed ID: 31583925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DEVELOPMENT OF SOLID LIPID NANOCARRIERS FOR ORAL DELIVERY OF CANDESERTAN CILEXETIL.
    Ugurlu T; Nalbantoglu A; Sengel-Turk CT
    Acta Pol Pharm; 2016 Nov; 73(6):1631-1638. PubMed ID: 29634119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and characterization of mixed niosomes for oral delivery using candesartan cilexetil as a model poorly water-soluble drug.
    Sezgin-Bayindir Z; Antep MN; Yuksel N
    AAPS PharmSciTech; 2015 Feb; 16(1):108-17. PubMed ID: 25204859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanoemulsion improves the oral absorption of candesartan cilexetil in rats: Performance and mechanism.
    Gao F; Zhang Z; Bu H; Huang Y; Gao Z; Shen J; Zhao C; Li Y
    J Control Release; 2011 Jan; 149(2):168-74. PubMed ID: 20951749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral bioavailability and intestinal absorption of candesartan cilexetil: role of naringin as P-glycoprotein inhibitor.
    Gurunath S; Nanjwade BK; Patil PA
    Drug Dev Ind Pharm; 2015 Jan; 41(1):170-6. PubMed ID: 24168234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mixed Pluronic/lecithin micelles formulation for oral bioavailability of candesartan cilexetil drug:
    Mahajan H; Patel HS; Ray D; Aswal VK; Sharma RK; Tandel H
    Drug Dev Ind Pharm; 2024 Jan; 50(1):23-35. PubMed ID: 38079333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Candesartan cilexetil loaded nanodelivery systems for improved oral bioavailability.
    Dudhipala N; Veerabrahma K
    Ther Deliv; 2017 Feb; 8(2):79-88. PubMed ID: 28088883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preparation, characterization and
    Amer AM; Allam AN; Abdallah OY
    Drug Dev Ind Pharm; 2019 Jul; 45(7):1140-1148. PubMed ID: 30912678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three dimensional macroporous hydroxyapatite/chitosan foam-supported polymer micelles for enhanced oral delivery of poorly soluble drugs.
    Zhang Y; Dong K; Wang F; Wang H; Wang J; Jiang Z; Diao S
    Colloids Surf B Biointerfaces; 2018 Oct; 170():497-504. PubMed ID: 29960950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Self-Nanoemulsifying Drug Delivery System for Enhancing the Oral Bioavailability of Candesartan Cilexetil: Ex Vivo and In Vivo Evaluation.
    AboulFotouh K; Allam AA; El-Badry M; El-Sayed AM
    J Pharm Sci; 2019 Nov; 108(11):3599-3608. PubMed ID: 31348934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Candesartan cilexetil microemulsions for transdermal delivery: formulation, in-vitro skin permeation and stability assessment.
    Malakar J; Basu A; Nayak AK
    Curr Drug Deliv; 2014; 11(3):313-21. PubMed ID: 24893994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of Oral Lipid Based Nano-formulation of Dapagliflozin: Optimization, in vitro Characterization and ex vivo Intestinal Permeation Study.
    Zafar A
    J Oleo Sci; 2020; 69(11):1389-1401. PubMed ID: 33132278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.